Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

CRG-023 Is a Novel Tri-Specific CAR T Product Candidate Engineered to Prevent Antigen Escape and Sustain Durable Anti-Tumor Functionality Against B-Cell Malignancies

Idit Sagiv Barfi, Eric Liao, Michael S Mannon, Boi Quach, Lingyan Wang, Samantha Koo-McCoy, Michael C Yi, James S Byers, III, Nhung Nguyen, Trevor M Bentley, Savannah Yung, Yu Huang, Michael T Bethune, Matthew Siegel, Michael O Ports

Blood (2024) 144 (Supplement 1): 2035.

https://doi.org/10.1182/blood-2024-206068

Published: 2024

Journal Articles

In Situ Vaccination with IL-12Fc and TLR Agonist - a Crucial Role for B Cells in Generating Anti-Tumor T Cell Immunity

Idit Sagiv Barfi, Debra K. Czerwinski, Ronald Levy

Blood (2021) 138 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2021-146628

Published: 2021

Journal Articles

In Situ Vaccination with Cpg and Anti-OX40 Antibody: Preclinical Optimization for Clinical Translation

Idit Sagiv Barfi, PhD, Debra K. Czerwinski, BA, Tanaya Shree, MD PhD BA, Ronald Levy, MD

Blood (2018) 132 (Supplement 1): 2943.

https://doi.org/10.1182/blood-2018-99-117872

Published: 2018

Journal Articles

Eradication of Systemic Lymphoma By Local Immunotherapy

Idit Sagiv Barfi, PhD, Debra K. Czerwinski, BA, Ronald Levy, MD

Blood (2017) 130 (Supplement 1): 113.

https://doi.org/10.1182/blood.V130.Suppl_1.113.113

Published: 2017

Journal Articles

Activity of a Sting and a TLR9 Agonist As an “in Situ Therapeutic Vaccination” Against Lymphomas

Adrienne Sallets, PhD, Idit Sagiv Barfi, PhD, Ron Levy, MD

Blood (2016) 128 (22): 48.

https://doi.org/10.1182/blood.V128.22.48.48

Published: 2016

Journal Articles

In Situ Vaccination with a TLR9 Agonist and Anti-OX40 Antibody Leads to Tumor Regression and Induces Abscopal Responses in Murine Lymphoma

Idit sagiv-Barfi, Debra K Czerwinski, Ronald Levy, MD

Blood (2016) 128 (22): 1847.

https://doi.org/10.1182/blood.V128.22.1847.1847

Published: 2016

Journal Articles

Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses

Idit Sagiv-Barfi, Hailing Lu, MDPhD, Jessica Hewitt, Frank J Hsu, MD, Jan ter Meulen, MD, Ronald Levy, MD

Blood (2015) 126 (23): 820.

https://doi.org/10.1182/blood.V126.23.820.820

Published: 2015

Journal Articles

T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC

Liora M. Schultz, MD, Niclas Olsson, PhD, Michael Khodadoust, MD PhD, Rupa Narayan, MD, Idit Sagiv-Barfi, Joshua Elias, PhD, Ronald Levy, MD

Blood (2015) 126 (23): 2228.

https://doi.org/10.1182/blood.V126.23.2228.2228

Published: 2015

Journal Articles

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma

Idit Sagiv-Barfi, Holbrook E. Kohrt, Laura Burckhardt, Debra K. Czerwinski, Ronald Levy

Blood (2015) 125 (13): 2079–2086.

https://doi.org/10.1182/blood-2014-08-593137

Published: 2015

Includes: Supplemental data

Journal Articles

Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tumor Irradiation

Boris Minev, MD, Holbrook Kohrt, MD, Mehmet Kilinc, PhD, Nanhai Chen, PhD, Audrey Feng, Maysam Pessian, Ulrike Geissinger, Erik Haefner, Desislava Tsoneva, Kliment Bozhilov, Idit Sagiv Barfi, PhD, Xing Zhao, Narendiran Rajasekaran, PhDMSc, Ronald Levy, MD, Aladar Szalay, PhD

Blood (2014) 124 (21): 4487.

https://doi.org/10.1182/blood.V124.21.4487.4487

Published: 2014

Journal Articles

Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Narendiran Rajasekaran, PhDMSc, Mohith Sadaram, BS, Jonathan Hebb, MD, Idit Sagiv-Barfi, PhD, Sid Ambulkar, Amanda Rajapaksa, Serena Chang, PhD, Cariad Chester, Erin Waller, Lai Wang, PhD, Brian Lannutti, PhD, Dave Johnson, Ron Levy, MD, Holbrook E Kohrt, MD PhD

Blood (2014) 124 (21): 3118.

https://doi.org/10.1182/blood.V124.21.3118.3118

Published: 2014

Journal Articles

Ibrutinib Enhances the Anti-Tumor Immune Response Induced By Intratumoral Injection of a TLR9 Ligand

Idit Sagiv-Barfi, Holbrook Kohrt, MD, Laura Burckhardt, Debra K Czerwinski, Ron Levy, MD

Blood (2014) 124 (21): 3121.

https://doi.org/10.1182/blood.V124.21.3121.3121

Published: 2014

Journal Articles

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Sylvia Herter, PhD, Idit Sagiv-Barfi, PhD, Cariad Chester, Mohith Sadaram, BS, Jonathan Hebb, MD, Debra K Czerwinski, Narendiran Rajasekaran, PhDMSc, Marina Bacac, PhD, Pablo Umana, PhD, Ron Levy, MD, Christian Klein, PhD, Holbrook E Kohrt, MD PhD

Blood (2014) 124 (21): 1765.

https://doi.org/10.1182/blood.V124.21.1765.1765

Published: 2014

Journal Articles

Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

Holbrook E. Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, Sarah E. M. Herman, Jonathon P. Butchar, Carolyn Cheney, Xiaoli Zhang, Joseph J. Buggy, Natarajan Muthusamy, Ronald Levy, Amy J. Johnson, John C. Byrd

Blood (2014) 123 (12): 1957–1960.

https://doi.org/10.1182/blood-2014-01-547869

Published: 2014

Journal Articles

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Holbrook E. Kohrt, Ariane Thielens, Aurelien Marabelle, Idit Sagiv-Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, Eric Vivier, François Romagné, Ronald Levy, Mathieu Bléry, Pascale André

Blood (2014) 123 (5): 678–686.

https://doi.org/10.1182/blood-2013-08-519199

Published: 2014

Includes: Supplemental data

Journal Articles

Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies

Holbrook E Kohrt, MD, PhD, Ariane Thielens, Aurelien Marabelle, MD, MSc, Idit Sagiv Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra K Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, PhD, Eric Vivier, PhD, Francois Romagne, PhD, Ronald Levy, MD, Pascale Andre, PhD, Mathieu Blery, PhD

Blood (2013) 122 (21): 4417.

https://doi.org/10.1182/blood.V122.21.4417.4417

Published: 2013

Journal Articles

Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Holbrook E Kohrt, MD, PhD, Idit Sagiv-Barfi, PhD, Sarwish Rafiq, MS, Sarah E.M. Herman, Jonathan P Butchar, Ph.D., Carolyn Cheney, B.S, Xiaoli Zhang, PhD, MS, Joseph J. Buggy, PhD, Natarajan Muthusamy, DVM, Ph.D, Ronald Levy, MD, Amy J Johnson, PhD, John C. Byrd, MD

Blood (2013) 122 (21): 373.

https://doi.org/10.1182/blood.V122.21.373.373

Published: 2013

NARROW

CRG-023 Is a Novel Tri-Specific CAR T Product Candidate Engineered to Prevent Antigen Escape and Sustain Durable Anti-Tumor Functionality Against B-Cell Malignancies

In Situ Vaccination with IL-12Fc and TLR Agonist - a Crucial Role for B Cells in Generating Anti-Tumor T Cell Immunity

In Situ Vaccination with Cpg and Anti-OX40 Antibody: Preclinical Optimization for Clinical Translation

Eradication of Systemic Lymphoma By Local Immunotherapy

Activity of a Sting and a TLR9 Agonist As an “in Situ Therapeutic Vaccination” Against Lymphomas

In Situ Vaccination with a TLR9 Agonist and Anti-OX40 Antibody Leads to Tumor Regression and Induces Abscopal Responses in Murine Lymphoma

Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses

T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma

Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tumor Irradiation

Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Ibrutinib Enhances the Anti-Tumor Immune Response Induced By Intratumoral Injection of a TLR9 Ligand

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies

Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only